natgillin/translations-raw huggingface dataset:
The pyridazinone or pyridone compound or the pyridazinone or pyridone compound for use according to claim 11, wherein R34 is selected from the group consisting of dimethylamino, methoxy, piperidinyl, N-methyl piperazinyl, N-benzoyl piperazinyl, and morpholinyl, or pharmaceutically acceptable salt, hydrate, or solvate thereof. 
Spoj piridazinona ili piridona ili spoj piridazinona ili piridona za uporabu prema zahtjevu 11, gdje R34 je odabran iz grupe koju čine dimetilamino, metoksi, piperidinil, N-metil piperazinil, N-benzoil piperazinil, i morfolinil, ili njegova farmaceutski prikladna sol, hidrat ili solvat.
The pyridazinone or pyridone compound of formula (I) or pharmaceutically acceptable salt, hydrate, or solvate thereof as defined in any one of claims 2 to 14 for use in the treatment or prevention a SSAO/VAP-1 related disease, wherein the disease is a diseases related to carbohydrate metabolism and complications thereof, a disease related to aberrations in adipocyte differentiation or function, a vascular disease, inflammation, a disease caused by inflammation, or a disease which causes inflammation, or immune, autoimmune disorder, or a fibrotic condition. 
Spoj piridazinona ili piridona formule (I) ili njegova farmaceutski prikladna sol, hidrat ili solvat kako je definirano prema bilo kojem od zahtjeva 2 do 14, za uporabu u liječenju ili prevenciji bolesti povezane s SSAO/VAP-1, gdje ta bolest jest bolest povezana s metabolizmom ugljikohidrata i njihovim komplikacijama, bolest povezana s promjenama diferencijacije ili funkcije adipocita, krvožilna bolest, upala, bolest uzrokovana upalom, ili bolest koja uzrokuje upalu, ili imuni, autoimuni poremećaj ili fibrotičko stanje.
A process for the preparation of sterile Brinzolamide bulk powder comprising the terminal gamma-ray sterilization treatment of Brinzolamide characterized by the Brinzolamide being a bulk powder further being packed in a protective atmosphere wherein the atmosphere that replaces ambient air is selected from vacuum, argon, nitrogen or helium. 
Postupak pripreme sterilne mase (bulk) praška brinzolamida koji obuhvaća sterilizacijsku obradu brinzolamida terminalnim gama zračenjem naznačeno time što je brinzolamid masa (bulk) praška koja se dalje pakira u zaštićenoj atmosferi gdje se atmosfera koja zamjenjuje okolni zrak odabire između vakuuma, argona, dušika ili helija.
A process according to claim 1 wherein the gamma-ray sterilization treatment is carried out in a sealed bag made of polyethylene and this container is in its turn sealed in another bag made of oxygen and humidity proof high barrier material. 
Postupak prema zahtjevu 1, gdje se sterilizacijska obrada gama zračenjem provodi u zatvorenoj polietilenskoj vrećici i ovaj spremnik se zatvara u drugu vrećicu napravljenu od materijala visoko nepropusnog za kisik i vlagu.
A process according to claim 1, wherein gamma-ray sterilization treatment is carried out with a radiation of 25 kGy. 
Postupak prema zahtjevu 1, gdje se sterilizacijska obrada gama zračenjem provodi sa zračenjem od 25 kGy.
A process according to claim 2 wherein the high barrier material is polylaminated aluminium or metallized foil coupled with polyester and polypropylene or polyethylene. 
Postupak prema zahtjevu 2, gdje je visoko nepropusni materijal polilaminirani aluminij ili metalizirana folija spojena s poliesterom i polipropilenom ili polietilenom.
A process according to claims 1-4, wherein the gamma-ray sterilization treatment is carried out on the Brinzolamide's powder packed under vacuum. 
Postupak prema zahtjevima 1-4, gdje se sterilizacijska obrada gama zračenjem provodi na prašku brinzolamida pakiranom pod vakuumom.
A process according to claims 1-4, wherein the gamma-ray sterilization treatment is carried out on the Brinzolamide's powder packed in nitrogen or helium atmosphere. 
Postupak prema zahtjevima 1-4, gdje se sterilizacijska obrada gama zračenjem provodi na prašku brinzolamida pakiranom u atmosferi dušika ili helija.
A process according to the claims 1-6, wherein the gamma-ray sterilization treatment is carried out at room temperature or below zero up to -78°C. 
Postupak prema zahtjevima 1-6, gdje se sterilizacijska obrada gama zračenjem provodi na sobnoj temperaturi ili ispod nule do -78°C.
A process according to claims 3, 6 and 7, wherein the gamma-ray sterilization treatment is carried out at -78°C, with a radiation of 25 kGy and on the Brinzolamide's powder packed in helium atmosphere. 
Postupak prema zahtjevima 3, 6 i 7, gdje se sterilizacijska obrada gama zračenjem provodi na -78°C, sa zračenjem od 25 kGy i na prašku brinzolamida pakiranom u atmosferi helija.
Mechanism according to claim 1, wherein said rotation control device (71) is provided with an encoder. 
Mehanizam sukladno zahtjevu 1, pri čemu je rotacijski kontrolni ueđaj (71) opremljen pružateljem.
is NR3′, and and R3′ together with the nitrogen, to which they are attached, form a 5 or 6 membered saturated heterocyclic ring, —N3, or triazole, said triazole being optionally substituted with R32, wherein R32 is selected from the group consisting of phenyl, C1-6-alkyl, and —CO2(C1-3-alkyl); or 
i R3’ zajedno s atomom dušika za koji su spojeni, formiraju zajedno skupinu odabranu iz grupe koju čine N-metil piperazinil, pirolidinil, po izboru supstituirani 1,2,3-triazolil, taj 1,2,3-triazolil je po izboru supstituiran s R32, gdje R32 je odabran iz grupe koju čine fenil, C1-6-alkil, i -CO2(C1-3-alkil); ili
wherein R35 and R35′ are both H or C1-6-alkyl; or R35 and R35′ together with the nitrogen, to which they are attached, form a 5 or 6 membered saturated heterocyclic ring optionally further comprising as a ring member O, S, N, or NR36, wherein R36 is H, C1-6-alkyl or benzoyl; 
gdje su R35 i R35’ oba H ili C1-6-alkil; ili R35 i R35’ zajedno s dušikom za koji su spojeni, formiraju 5 ili 6-eročlani zasićeni heterociklički prsten koji po izboru sadrži dodatno kao člana prstena O, S, N, ili NR36, gdje R36 je H, C1-6-alkil ili benzoil;
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
The process of any one of claims 2-4, wherein the filtering step (ii) further comprises the step of receiving the aqueous pharmaceutical solution filtered through the first filter in a receiving vessel, and further comprises the step of reducing the temperature of the aqueous pharmaceutical solution to a temperature of above 0°C to 17.5°C after leaving the receiving vessel and before entering into the second filter. 
Postupak prema bilo kojem od patentnih zahtjeva 2-4, naznačen time, da stupanj filtriranja (ii) nadalje sadrži stupanj primanja vodene farmaceutske otopine filtrirane kroz prvi filter u prihvatnu posudu, i nadalje sadrži stupanj smanjivanja temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, nakon izlaska iz prihvatne posude, a prije ulaska u drugi filter.
compounding the aqueous pharmaceutical solution in a compounding vessel and reducing the temperature of the aqueous pharmaceutical solution to a temperature of above 0°C to 17.5°C after leaving the compounding vessel and before entering into the first filter; or 
miješanje vodene farmaceutske otopine u posudi za miješanje i smanjivanje temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, nakon izlaska iz posude za miješanje, a prije ulaska u prvi filter; ili
compounding the aqueous pharmaceutical solution in a compounding vessel and reducing the temperature of the aqueous pharmaceutical solution to a temperature of above 0°C to 17.5°C while in the compounding vessel. 
miješanje vodene farmaceutske otopine u posudi za miješanje i smanjivanje temperature vodene farmaceutske otopine na temperaturu od iznad 0°C do 17,5°C, dok je u posudi za miješanje.
the pressure during the filtering step (ii) and the pressure during the filling step (iii) is maintained below 5.0 bar; or preferably below 3.0 bar; or more preferably below 2.0 bar; or 
pritisak za vrijeme stupnja filtriranja (ii) i pritisak za vrijeme stupnja punjenja (iii) se održava ispod 5,0 bara; ili ispod 3,0 bara; ili ispod 2,0 bara; ili
the pharmaceutical preparation is a lyophilized powder of glatiramer acetate and mannitol, and (ii) the process further comprises a step of lyophilizing the filtrate after it has been filled into the suitable container so as to form a lyophilized powder of glatiramer acetate and mannitol in the suitable container. The process of any one of claims 1-12, wherein 
Postupak prema bilo kojem od patentnih zahtjeva 1-11, naznačen time, da farmaceutski pripravak jest liofilizirani prašak glatiramer acetata i manitola, a da postupak nadalje sadrži stupanj liofiliziranja filtrata nakon stoje taj bio napunjen u prikladni spremnik, tako da se oblikuje liofilizirani prašak glatiramer acetata i manitola u prikladnom spremniku.
A method for the detection of a primer extension product produced in the presence of a polymerase lacking 3'→5' exonuclease activity, the method comprising the steps of: 
Postupak za detekciju proizvoda elongacije početnice koja se proizvodi u prisutnosti polimeraze koja nema 3’→5’ egzonukleaznu aktivnost, pri čemu navedeni postupak sadrži korake:
providing at least two single-labelled oligonucleotide sequences that hybridise to one another in free solution to form a fluorescent quenched pair, that upon introduction of a complementary sequence to one or both sequences generates a measurable signal when the complementary sequence is hybridised to one of the at least two single-labelled oligonucleotide sequences, wherein at least one of the oligonucleotide sequences contains at least one phosphorothioate group; 
osiguravanja barem dvije oligonukleotidne sekvence koje su jednom obilježene, koje hibridiziraju međusobno slobodno u otopini da nastane fluorescentno prigušeni par, koji nakon uvođenja komplementarne sekvence s jednom ili obje sekvence, stvara signal koji se može izmjeriti kada komplementarna sekvenca hibridizira s jednom od barem dvije oligonukleotidne sekvence koje su jednom obilježene, pri čemu barem jedna od oligonukleotidnih sekvenci sadrži barem jednu fosforotioatnu skupinu;
providing at least one primer and initiating the primer extension reaction from the at least one primer using a polymerase lacking 3' to 5' exonuclease activity thereby generating a complementary sequence to at least one of the single-labelled oligonucleotide sequences; and 
osiguravanja barem jedne početnice i započinjanje reakcije elongacije početnice od barem jedne početnice pomoću polimeraze koja nema 3’ → 5’ egzonukleaznu aktivnost, čime se stvara komplementarna sekvenca s barem jednom od oligonukleotidnih sekvenci koje su jednom obilježene; i
A kit for the detection of a primer extension product produced in the presence of a polymerase lacking 3'→5' exonuclease activity, that comprises 
Komplet za detekciju proizvoda elongacije početnice koji se proizvodi u prisutnosti polimeraze koja nema 3’→5’ egzonukleaznu aktivnost, koji sadrži:
wherein at least one of the oligonucleotide sequences contains at least one phosphorothioate group, wherein at least one of the internal bases of the at least one oligonucleotide sequence contains a phosphorothioate group and wherein the at least one oligonucleotide sequence that contains at least one phosphorothioate group has 20-80%, optionally 30-70%, of the bases modified by a phosphorothioate group; and optionally wherein the modified bases are separated by at least one unmodified base, and/or 
gdje barem jedna od oligonukleotidnih sekvenci sadrži barem jednu fosforotioatnu skupinu, gdje barem jedna od unutrašnjih baza barem jedne oligonukleotidne sekvence sadrži fosforotioatnu skupinu i gdje barem jedna oligonukleotidna sekvenca koja sadrži barem jednu fosforotioatnu skupinu ima 20-80%, proizvoljno 30-70%, baza koje su modificirane fosforotioatnom grupom; i proizvoljno gdje su modificirane baze odvojene barem jednom nemodificiranom bazom i/ili gdje su naizmjenične baze fosforotioati.
wherein one of the first and second oligonucleotide sequences has a Tm that is at or below the Ta (annealing temperature) of the primer extension reaction, or 
gdje jedna od prve i druge oligonukleotidne sekvence ima Tm koja je na ili ispod Ta (temperature spajanja) reakcije elongacije početnice, ili
initiating the primer extension reaction from the at least one primer using a polymerase lacking 3' to 5' exonuclease activity thereby generating a complementary sequence to the first single-labelled oligonucleotide sequence; and 
iniciranja reakcije elongacije početnice od barem jedne početnice pomoću polimeraze koja nema 3’ → 5’ egzonukleaznu aktivnost čime se stvara komplementarna sekvenca s prvom oligonukleotidnom sekvencom koja je jednom obilježena; i
modified to be resistant to nuclease degradation; and/or are labelled with molecules that are distance sensitive. 
modificirani da budu otporni na degradaciju nukleazom; i/ili su obilježeni molekulama koje su osjetljive na udaljenost.
A pharmaceutical composition for use in the treatment of chronic obstructive pulmonary disease, comprising: 
Farmaceutski sastav, naznačen time, da se upotrebljava za liječenje kronične opstrukcijske plućne bolesti, pri čemu on obuhvaća sljedeće:
a compound selected from: 
spoj odabran od sljedećih:
The pharmaceutical composition for use according to claim 7, wherein the composition comprises the compound 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav za uporabu prema zahtjevu 7, naznačen time, da sastav obuhvaća spoj 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegovu farmaceutski prihvatljivu sol, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
The pharmaceutical composition for use according to claim 7, wherein the composition comprises the compound 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav za uporabu prema zahtjevu 7, naznačen time, da sastav obuhvaća spoj 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegovu farmaceutski prihvatljivu sol, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
The pharmaceutical composition for use according to claim 7, wherein the composition comprises the compound 3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav za uporabu prema zahtjevu 7, naznačen time, da sastav obuhvaća spoj 3-amino-6-(4-fluoro-fenil)-5-trifluorometil-piridin-2-karboksilna kiselina-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegovu farmaceutski prihvatljivu sol, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
The pharmaceutical composition for use according to claim 7, wherein the composition comprises 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav za uporabu prema zahtjevu 7, naznačen time, da sastav obuhvaća spoj 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegovu farmaceutski prihvatljivu sol, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
The pharmaceutical composition for use according to claim 7, wherein the composition comprises the compound 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav za uporabu prema zahtjevu 7, naznačen time, da sastav obuhvaća spoj 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegovu farmaceutski prihvatljivu sol, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
Use of a compound, or a pharmaceutically acceptable salt thereof, selected from: 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, pri čemu je spoj odabran od sljedećih:
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-(4-fluoro-fenil)-5-trifluorometil-piridin-2-karboksilna kiselina-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
a first active comprising a compound selected from: 
prvo djelatno sredstvo koje obuhvaća spoj odabran od sljedećih:
A system for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section, comprising: 
Sustav za proizvodnju okvira (27c) od materijala kao što su žica ili traka, ili drugi materijali prizmatičnog poprečnog presjeka, koji sadrži:
a feeding station (Ph1) configured to introduce material sections; 
Stanica za opskrbu (Ph1) konfigurirana za uvođenje isječaka materijala;
a joining station (Ph2) for joining together the ends (1) of material sections introduced into the machine, so as to produce frame loops (27b); 
Stanica za sastavljanje (Ph2) za sastavljanje krajeva (1) isječaka materijala, uvedenih u stroj, tako da se proizvode lukovi okvira (27b);
a bending station (Ph3) for controllably bending frame (27c) angles in frame loops (27b) produced by said joining station (Ph2); 
Stanica za savijanje (Ph3) za kontrolirano savijanje kutova okvira (27c), u lukove okvira (27b), proizvedenih u navedenoj stanici za sastavljanje (Ph2);
a material guide (5) extending between said feeding station (Ph1) and said joining station (Ph2), said material guide (5) having a channel; 
Vodilica za materijal (5), proteže se između navedene stanice za opskrbu (Ph1) i navedene stanice za sastavljanje (Ph2), navedena vodilica za materijal (5) ima kanal;
a clamping mechanism (15) configured to retain a first unjoined end of material section passed through said material guide (5); 
Mehanizam za stezanje (15), konfiguriran tako, da zadrži prvi nesastavljeni kraj dijela materijala, prolazećeg kroz navedenu vodilicu materijala (5);
a release mechanism or mechanisms (7,8) configured to controllably release material from said channel or said material guide (5); 
Mehanizam, ili mehanizmi za otpuštanje (7, 8) konfigurirani za kontrolirano otpuštanje materijala iz navedenog kanala ili navedene vodilice materijala (5);
A system for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section as claimed in claim 3, further characterized by: 
Sustav za proizvodnju okvira (27c), od materijala, kao što su žica ili traka, ili drugi materijali prizmatičnog poprečnog presjeka, kao što se zahtjeva u zahtjevu 3, naznačen time:
said feeding station (Ph1) has advancement rollers (3), a straightener (2), and measuring rollers (4). 
Navedena stanica za opskrbu (Ph1), ima valjke za pomjeranje (3), ravnalo (2) i valjke za mjerenje (4).
A system for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section as claimed in claims 1 or 2, further characterized by: 
Sustav za proizvodnju okvira (27c), od materijala, kao što su žica ili traka, ili drugi materijali prizmatičnog poprečnog presjeka, kao što se zahtjeva u zahtjevima 1 ili 2, naznačeni time:
said joining station (Ph2) has a welding head with electrodes (17, 18). 
Navedena stanica za sastavljanje (Ph2) ima glavu za zavarivanje sa elektrodama (17, 18).
A system for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section as claimed in any one of claims 1 to 7, further characterized by: 
Sustav za proizvodnju okvira (27c), od materijala, kao što su žica ili traka, ili drugi materijali prizmatičnog poprečnog presjeka, kao što se zahtjeva u zahtjevima 1 do 7, naznačeni time:
said material guide (5) has a circular or ellipsoid form and embodies cross section of concave form. 
Navedena vodilica materijala (5) ima kružni ili elipsoidni oblik i formira poprečni presjek konkavnog oblika.
introducing a material section (27a) via a feeding station (Ph1); 
Uvođenje isječka materijala (27a) preko stanice za opskrbu (Ph1);